N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with pre-existing renal insufficiency or diabetes: A systematic review and meta-analysis

Renal Failure

Volumn 37, Issue 10, 2015, Pages 297-303

  Kang, Xin ^a   Hu, Da Yong ^a   Li, Chang Bin ^a   Ai, Zi Sheng ^a   Peng, Ai ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

Contrast induced nephropathy; diabetes; meta analysis; N acetylcysteine; renal insufficiency

Indexed keywords

ACETYLCYSTEINE; CONTRAST MEDIUM;

ARTICLE; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST INDUCED NEPHROPATHY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; INCIDENCE; KIDNEY FAILURE; META ANALYSIS; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; CHEMICALLY INDUCED; COMPLICATION; DIABETIC NEPHROPATHY; KIDNEY DISEASES;

ACETYLCYSTEINE; CONTRAST MEDIA; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY;

EID: 84947126666     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2015.1012985     Document Type: Article

References (43)

1. McCullough PA, Adam A, Becker CR, et al. CIN consensus working panel: Risk prediction of contrast-induced nephropathy. Am J Cardiol. 2006; 98: 27K-36K
2. Golshahi J, Nasri H, Gharipour M. Contrast-induced nephropathy: A literature review. J Nephropathol. 2014; 3: 51-56
3. Schilp J, de Blok C, Langelaan M, Spreeuwenberg P, Wagner C. Guideline adherence for identification and hydration of high-risk hospital patients for contrast induced nephropathy. BMC Nephrol. 2014; 15: 2
4. McCullough PA, Adam A, Becker CR, et al. CIN consensus working panel. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol. 2006; 98: 5K-13K
5. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic contrast-Agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000; 343: 180-184
6. Briguori C, Visconti G, Focaccio A, et al. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): Renal guard system in high-risk patients for contrast-induced acute kidney injury. Circulation. 2011; 124: 1260-1269
7. Jo SH. N-Acetylcysteine for prevention of contrast-induced nephropathy: A narrative review. Korean Circ J. 2011; 41: 695-702
8. Pannu N, Manns B, Lee H, Tonelli M. Systematic review of the impact of N-Acetylcysteine on contrast nephropathy. Kidney Int. 2004; 65: 1366-1374
9. Kshirsagar AV, Poole C, Mottl A, et al. N-Acetylcysteine for the prevention of radiocontrast induced nephropathy: Meta-Analysis of prospective controlled trial. J Am Soc Nephrol. 2004; 15: 761-769
10. Brueck M, Cengiz H, Hoeltgen R, et al. Usefulness of N-Acetylcysteine or ascorbic-Acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: A single-center, prospective, randomized, double-blind, placebo-controlled trial. J Invasive Cardiol. 2013; 25: 276-283
11. ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: Main results from the randomized acetylcysteine for contrast-induced nephropathy trial (ACT). Circulation. 2012; 124: 1250-1259
12. Solomon R, Barrett B. Follow-up of patients with contrast-induced nephropathy. Kidney Int Suppl. 2006; (100): S46-S50
13. Pannu N, Wiebe N, Tonelli M. Alberta kidney disease network: Prophylaxis strategies for contrast-induced nephropathy. JAMA. 2006; 295: 2765-2779
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-Analyses. BMJ. 2003; 327: 557-560
15. Allaqaband S, Tumuluri R, Malik AM, et al. Prospective randomized study of N-Acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv. 2002; 57: 279-283
16. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: The RAPPID study. J Am Coll Cardiol. 2003; 41: 2114-2118
17. Baskurt M, Okcun B, Abaci O, et al. N-Acetylcysteine versus N-Acetylcysteine + theophylline for the prevention of contrast nephropathy. Eur J Clin Invest. 2009; 39: 793-799
18. Carbonell N, Sanjuán R, Blasco M, Jordá A, Miguel A. N-Acetylcysteine: Short-term clinical benefits after coronary angiography in high-risk renal patients. Rev Esp Cardiol. 2010; 63: 12-19
19. Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial of N-Acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 2002; 62: 2202-2207
20. Ferrario F, Barone MT, Landoni G, et al. Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy-A randomized controlled study. Nephrol Dial Transplant. 2009; 24: 3103-3107
21. Fung JW, Szeto CC, Chan WW, et al. Effect of N-Acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: A randomized trial. Am J Kidney Dis. 2004; 43: 801-808
22. Jaffery Z, Verma A, White CJ, et al. A randomized trial of intravenous N-Acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes. Catheter Cardiovasc Interv. 2012; 79: 921-926
23. Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: A randomized controlled trial. JAMA. 2003; 289: 553-558
24. Kimmel M, Butscheid M, Brenner S, Kuhlmann U, Klotz U, Alscher DM. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-Acetylcysteine or zinc-preliminary results. Nephrol Dial Transpl. 2008; 23: 1241-1245
25. Koc F, Ozdemir K, Kaya MG, et al. Intravenous N-Acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS-A multicenter prospective controlled trial. Int J Cardiol. 2012; 155: 418-423
26. Miner SE, Dzavik V, Nguyen-Ho P, et al. N-Acetylcysteine reduces contrast-Associated nephropathy but not clinical events during long-term follow-up. Am Heart J. 2004; 148: 690-695
27. Ochoa A, Pellizzon G, Addala S, et al. Abbreviated dosing of N-Acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention. J Interv Cardiol. 2004; 17: 159-165
28. Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN, Cichowski E, Hilleman DE. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J. 2003; 146: E23
29. Poletti PA, Saudan P, Platon A, et al. N-Acetylcysteine and emergency CT: Use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity. AJR Am J Roentgenol. 2007; 189: 687-692
30. Rashid ST, Salman M, Myint F, et al. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: A randomized controlled trial of intravenous N-Acetylcysteine. J Vasc Surg. 2004; 40: 1136-1141
31. Seyon RA, Jensen LA, Ferguson IA, Williams RG. Efficacy of N-Acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention. Heart Lung. 2007; 36: 195-204
32. Webb JG, Pate GE, Humphries KH, et al. A randomized controlled trial of intravenous N-Acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: Lack of effect. Am Heart J. 2004; 148: 422-429
33. Coyle LC, Rodriguez A, Jeschke RE, Simon-Lee A, Abbott KC, Taylor AJ. Acetylcysteine In Diabetes (AID): A randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics. Am Heart J. 2006; 151: 1032. e9-e12
34. Carbonell N, Blasco M, Sanjuán R, et al. Intravenous N-Acetylcysteine for preventing contrast-induced nephropathy: A randomized trial. Int J Cardiol. 2007; 115: 57-62
35. Verhagen AP, de Vet HC, de Bie RA, et al. The Delphi list: A criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol. 1998; 51: 1235-1241
36. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996; 17: 1-12
37. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002; 105: 2259-2264
38. Friedewald VE, Goldfarb S, Laskey WK, McCullough PA, Roberts WC. The editors roundtable: Contrast-induced nephropathy. Am J Cardiol. 2007; 100: 544-551
39. Hoffmann U, Fischereder M, Krüger B, Drobnik W, Krämer BK. The value of N-Acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol. 2004; 15: 407-410
40. Weikl A, Hubmann M. A survey of contrast media used in coronary angiography. Cardiovasc Intervent Radiol. 1982; 5: 202-210
41. Stacul F, van der Molen AJ, Reimer P, et al. Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). Contrast induced nephropathy: Updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol. 2011; 21: 2527-2541
42. Sun Z, Fu Q, Cao L, Jin W, Cheng L, Li Z. Intravenous N-Acetylcysteine for prevention of contrast-induced nephropathy: A meta-Analysis of randomized, controlled trials. PLoS One. 2013; 8: e55124
43. Moist L, Sontrop JM, Gallo K, et al. Effect of N-Acetylcysteine on serum creatinine and kidney function: Results of a randomized controlled trial. Am J Kidney Dis. 2010; 56: 643-650